The down-regulation of MMP-9 protein levels by bortezomib, the first proteasome inhibitor in the clinic, has been documented in lung cancer [38], squamous cell carcinoma [39], bladder carcinoma [40], breast cancer cells [41] and myeloma cells [42]. This evidence concerns the gene MMP9 and urinary bladder carcinoma.